98%
921
2 minutes
20
Lassa fever (LF) is a fatal hemorrhagic disease caused by the Lassa virus (LASV), which mainly spreads in Africa. As China's interactions with Africa become more frequent, the risk of LF being imported into China also rises, making the study of LASV increasingly urgent. In this study, the Lineage IV LASV strain was successfully isolated from the first imported case in China. Compared with the LASV genome, the isolated strain may exhibit greater infectivity and interspecies transmission capabilities. We successfully established BALB/c, C57BL/6, and AG129 mouse infection models and found that intranasal inoculation was the most stable infection method. Select the anti-LASV drug LHF-535 for preliminary evaluation, further confirming the stability of the model. In summary, the isolated strain exhibits enhanced transmission capabilities and may spread between mice via the respiratory tract, meriting greater attention and emphasis. This study will bridge the gap in China's independent P4-level pathogen isolation, meet national biosafety and strategic needs, and provide certain support for LASV research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318830 | PMC |
http://dx.doi.org/10.1002/mco2.70315 | DOI Listing |
PLoS Negl Trop Dis
September 2025
Center for Artificial Intelligence in Public Health Research, Robert Koch Institute, Wildau, Germany.
Lassa fever, caused by the Lassa virus (LASV), is a deadly disease characterized by hemorrhages. Annually, it affects approximately 300,000 people in West Africa and causes about 5,000 deaths. It currently has no approved vaccine and is categorized as a top-priority disease.
View Article and Find Full Text PDFCell Host Microbe
August 2025
Department of Chemical and Structural Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel. Electronic address:
Lassa virus (LASV) is a devastating human pathogen with no vaccines and limited therapeutics. The LASV class-I spike complex engages target cells via binding its primary host receptor, matriglycan, followed by macropinocytosis and binding of its secondary receptor, lysosomal-associated membrane protein 1 (LAMP1), to trigger virus fusion. This process occurs across multiple pH-dependent steps, but the molecular events remain largely unknown.
View Article and Find Full Text PDFJ Gen Virol
September 2025
Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
Lassa virus (LASV) is circulating in rodents in several countries in West Africa and is the causative agent of the zoonotic disease Lassa fever. Several vaccine candidates have been successfully tested in preclinical and clinical research, while no LASV-specific vaccines or antiviral treatments have been licensed to date. Approximately 500,000 human cases of Lassa fever are estimated to occur every year.
View Article and Find Full Text PDFEBioMedicine
August 2025
Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. Electronic address:
Pathogens
July 2025
Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center (UNMC), Omaha, NE 68198, USA.
Sin Nombre virus (SNV) is the main causative agent of hantavirus cardiopulmonary syndrome (HCPS) in North America. SNV is transmitted via environmental biological aerosols (bioaerosols) produced by infected deer mice (). It is similar to other viruses that have environmental transmission routes rather than a person-to-person transmission route, such as avian influenza (e.
View Article and Find Full Text PDF